Faltering growth in the critically ill child: prevalence, risk factors, and impaired outcome

Frédéric V Valla1, Julien Berthiller2, Bénédicte Gaillard-Le-Roux3

  • 1Paediatric Intensive Care Unit, Hôpital Universitaire Femme Mère Enfant, Hospices Civils de Lyon, 59 bd Pinel, 69677, Lyon-Bron, France. frederic.valla@chu-lyon.fr.

Insights

Faltering growth, a dynamic measure of nutritional status, is common in critically ill children and independently linked to longer intensive care stays. This highlights the need for both static and dynamic nutritional assessments in pediatric intensive care units (PICUs).

Area of Science:

  • Pediatric critical care medicine
  • Nutritional science
  • Growth assessment

Background:

  • Low body mass index (BMI) z-score defines undernutrition, but faltering growth offers a complementary dynamic assessment.
  • Nutritional status impacts outcomes in critically ill children.

Purpose of the Study:

  • To investigate the prevalence of undernutrition and faltering growth in pediatric intensive care unit (PICU) admissions.
  • To determine the impact of undernutrition and faltering growth on patient outcomes.

Main Methods:

  • Prospective enrollment of 685 children (0-18 years) admitted to a single-center PICU over one year.
  • Nutritional status assessed via anthropometric measurements at admission.
  • Undernutrition defined as BMI-for-age z-score < -2SD; faltering growth as weight-for-age deceleration > -1 z-score in the prior 3 months.

Main Results:

  • Undernutrition diagnosed in 13% of children; faltering growth in 13.7%, often with normal BMI.
  • Faltering growth was associated with a history of chronic disease.
  • Faltering growth independently predicted an extended PICU length of stay in multivariate analysis.

Conclusions:

  • Nutritional assessment in critically ill children requires evaluation of both undernutrition and faltering growth.
  • Faltering growth is an independent factor associated with suboptimal outcomes, specifically longer PICU stays.
  • Dynamic assessment for faltering growth is crucial in pediatric critical care settings.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
323
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
335
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.5K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.2K